Key Highlights

  • Tempest Therapeutics (NASDAQ:TPST) is indicated at USD 0.4050, up 12.06% pre-market on November 10, 2026, with a Market Capitalisation of USD 7.23 million and no catalyst identified in published coverage.
  • PMV Pharmaceuticals (NASDAQ:PMVP) was quoted at USD 1.39, up 11.27%, with no catalyst identified and third-quarter results estimated for November 11, 2026.
  • Iambic Therapeutics (NASDAQ:IAM) climbed 10.69% to USD 14.81, still 7.4% under its USD 16.00 IPO price (calculated), while Autonomix Medical rose 10.00% to USD 1.87 after an 11.84% gain on November 9.
  • Autolus Therapeutics (NASDAQ:AUTL) is up 8.33% at USD 1.43 ahead of third-quarter results due before the open on November 10, with a call at 8:30 a.m. ET.

Tempest Therapeutics (NASDAQ:TPST): Up 12.06% Pre-Market With No Catalyst Identified

Tempest Therapeutics (NASDAQ:TPST) was indicated at USD 0.4050 pre-market, a USD 0.0436 per-share gain calculated from USD 0.3614 on November 9, 2026. Two searches found no company release, filing or published coverage dated November 9 or 10 that accounts for the move, so no catalyst is identified. In general, a stock far below USD 1.00 can bounce on short covering, a thin order book or a sympathy move in oncology. Market capitalisation is USD 7.23 million on 20.00 million shares, and the price sits 95.8% below the 52-week high of USD 9.75 and 12.5% above the low, both calculated. Cash and short-term investments on the quote page were only USD 779,000, which may be out of date. Volume was 5,451 shares against an average of 2.55 million, about 0.21% of a typical day. Dilution and a Nasdaq bid-price deficiency are the risks for Tempest Therapeutics (NASDAQ:TPST).

PMV Pharmaceuticals (NASDAQ:PMVP): Up 11.27% Pre-Market With No Catalyst Identified

PMV Pharmaceuticals (NASDAQ:PMVP) was quoted at USD 1.39 pre-market, 11.27% higher than a calculated USD 1.25 prior level, or roughly USD 0.14 a share. Neither a company release nor a filing dated November 9 or 10, 2026 turned up, so no catalyst is identified. Generally, clinical-stage biotechs can rise on Earnings positioning, short covering or a single buyer in a thin book. Third-quarter results are estimated for November 11, 2026, a date the company has not confirmed. On 75.51 million shares the quote implies about USD 104.96 million, calculated, against USD 85.33 million at the October 26 close of USD 1.13, and that share count may predate the August 31, 2026 offering. Cash was USD 112.9 million at December 31, 2025, down USD 70.4 million over the year. The price is 27.2% below the 52-week high of USD 1.91, calculated. Dilution and a Reversal at the open are risks for PMV Pharmaceuticals (NASDAQ:PMVP).

Iambic Therapeutics (NASDAQ:IAM): Up 10.69% Pre-Market With No Catalyst Identified

Iambic Therapeutics (NASDAQ:IAM) was quoted at USD 14.81 pre-market, 10.69% above a calculated USD 13.38 prior close, a level 16.4% under the USD 16.00 IPO price of October 15, 2026. No company release dated November 9 or 10 was found, so no catalyst is identified. As background, analyst research on a new listing usually starts after a 25-day quiet period, which ends November 9, 2026 (calculated), and initiations can move the shares. Updated IAM1363 Phase 1/1b data appeared around October 26, and ARK Investment reportedly bought 1.18 million shares. At 47.40 million shares the quote implies about USD 702.0 million, calculated, compared with USD 683.05 million on October 26, when volume was only 149,160 shares. The price is 40.8% below the 52-week high of USD 25.00, and lock-up expiries, thin trading and a clinical setback are the risks for Iambic Therapeutics (NASDAQ:IAM).

Autonomix Medical (NASDAQ:AMIX): Up 10.00% Pre-Market With No Catalyst Identified

Autonomix Medical (NASDAQ:AMIX) is indicated at USD 1.87 pre-market, 10.00% above a calculated USD 1.70 prior close that matches the November 9 close. The stock gained USD 0.18, or 11.84%, on November 9 on volume of 342,889 shares, so this is a two-day bounce. Neither a company release nor a filing dated November 9 or 10, 2026 was located, so no catalyst is identified. The latest items were FDA pre-submission feedback on a 510(k) pathway on September 30 and a Canadian Patent in early October. Market capitalisation is USD 3.33 million on 1.96 million shares, although the calculated value at this quote is about USD 3.7 million. The 52-week range runs from USD 1.46 to USD 32.55. Cash was USD 9.9 million at December 31, 2025 against a funding need of USD 30 million to USD 36 million, so dilution is the central risk for Autonomix Medical (NASDAQ:AMIX).

Autolus Therapeutics (NASDAQ:AUTL): Up 8.33% Pre-Market Ahead of Q3 Results

Autolus Therapeutics (NASDAQ:AUTL) is indicated at USD 1.43 pre-market, 8.33% above a calculated USD 1.32 prior close. The probable trigger is positioning ahead of third-quarter results due before the open on November 10, 2026, with a call at 8:30 a.m. ET. No reported figures have been confirmed, so none are stated here. In August 2026 the company raised its 2026 AUCATZYL net product Revenue guidance to USD 140 million to USD 150 million from USD 120 million to USD 135 million. At about 266.16 million shares the calculated Market Value is near USD 380.6 million, within a 52-week range of USD 1.175 to USD 2.58. Trailing revenue is USD 117.39 million against a net loss of USD 280.16 million. A Credit Facility of up to USD 250 million carries interest at one-month SOFR plus 7.25%. The company said its cash runway extends into the second quarter of 2028. A results miss, dilution and a reversal after the call are risks for Autolus Therapeutics (NASDAQ:AUTL).

Where Things Stand

The top healthcare pre-market gainer in this second group is Tempest Therapeutics (NASDAQ:TPST) at 12.06%, with no catalyst identified. The common thread is small size, light pre-market volume and reliance on outside capital. Autolus Therapeutics (NASDAQ:AUTL) is the only name with a scheduled event, third-quarter results on November 10, 2026. PMV Pharmaceuticals (NASDAQ:PMVP) reports on an estimated date a day later. Moves in thinly traded names can reverse at the open, since few shares trade and spreads are wide. These lists rely on a pre-market screener snapshot from November 10, 2026.